- FDA and EMA both approve additional biosimilar versions of Humira® (adalimumab).
- FDA also approves its third biosimilar version of Neupogen® (filgrastim).
- EMA has not approved any new biosimilars in 2022, but has recommended approval of teriparatide biosimilar Sondelbay and the








